Almirall and the Centre for Genomic Regulation have entered into a research collaboration to develop and characterize novel preclinical models for the identification of new nonmelanoma skin cancer treatments, according to a press release. “At Almirall, we regularly identify external collaborations that can leverage and complement our internal capabilities and research,” Karl
Almirall and the Centre for Genomic Regulation (CRG) collaborate to develop and characterize novel preclinical models for non-melanoma skin cancer · Non-melanoma skin cancer is the most frequent type of cancer, and its incidence is constantly increasing[i] ·.